Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064534 | 0.88 | ESR1 (0.58) | ESR1ESR2PAX8ALDH1A1RIPK1 | |
| SCHEMBL5205886 | 0.88 | ESR1 (0.58) | ESR1ESR2ALDH1A1TDP1BRD4 | |
| SCHEMBL13921507 | 0.88 | ESR1 (0.84) | ESR1ESR2PAX8ALDH1A1KMT2A | |
| SCHEMBL15841548 | 0.84 | GFER (0.60) | ESR1ESR2ALDH1A1TDP1GFER | |
| SCHEMBL1997854 | 0.84 | L3MBTL1 (0.56) | ESR1ESR2ALDH1A1GFERKMT2A | |
| SCHEMBL15841547 | 0.84 | GFER (0.60) | ESR1ESR2ALDH1A1TDP1GFER | |
| SCHEMBL29975007 | 0.84 | L3MBTL1 (0.56) | ESR1ESR2ALDH1A1GFERKMT2A | |
| SCHEMBL10574313 | 0.82 | HDAC6 (0.56) | ESR1ESR2ALDH1A1TSHRLMNA | |
| SCHEMBL3739324 | 0.81 | HDAC6 (0.54) | ESR1ESR2 | |
| SCHEMBL11133372 | 0.78 | RIPK1 (0.45) | ESR1ESR2ALDH1A1RIPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100509781-C | Process for preparing 1, 4-diphenylazetidinone derivatives | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-08 | — | — | CN | claimed |
| US-7488818-B2 | Method for producing 1,4-diphenyl azetidinone derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-02-10 | — | — | US | claimed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | claimed |
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | claimed |
| WO-2008057948-A2 | PROCESSES FOR PRODUCTION OF DIPHENYLYLAZETIDIN-2-ONES AND RELATED COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| EP-1756049-B1 | METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-10-31 | — | — | EP | claimed |
| US-20070149776-A1 | METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-28 | — | — | US | claimed |
| CN-1953961-A | Process for preparing 1, 4-diphenylazetidinone derivatives | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-04-25 | — | — | CN | claimed |
| US-20200113968-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | BAUSCH HEALTH IRELAND LTD (IE) | 2020-04-16 | — | — | US | disclosed |
| US-10597424-B2 | Agonists of guanylate cyclase and their uses | BAUSCH HEALTH IRELAND LIMITED (IE) | 2020-03-24 | — | — | US | disclosed |
| US-20190262420-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263861-A1 | AGONISTS OF GUANYLATE CYCLASE AND THEIR USES | JPMORGAN CHASE BANK, N.A. | 2019-08-29 | — | — | US | disclosed |
| US-10238712-B2 | Compositions useful for the treatment of gastrointestinal disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10118946-B2 | Agonists of guanylate cyclase and their uses | SYNERGY PHARMACEUTICALS INC. (US) | 2018-11-06 | — | — | US | disclosed |
| WO-2005021495-A3 | QUATERNARY SALT DERIVATIVES OF 1,4-DIPHENYLAZETIDIN-2-ONES | MICROBIA INC (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005021497-A2 | TETHERED DIMERS AND TRIMERS OF 1,4-DIPHENYLAZETIDN-2-ONES | MICROBIA, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021497-A2 | TETHERED DIMERS AND TRIMERS OF 1,4-DIPHENYLAZETIDN-2-ONES | MICROBIA, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021495-A2 | QUATERNARY SALT DERIVATIVES OF 1,4-DIPHENYLAZETIDIN-2-ONES | MICROBIA INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20040030126-A1 | Process for synthesizing beta-lactam | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1346981-A1 | PROCESS FOR SYNTHESIZING $g(b)-LACTAM | National Institute of Advanced Industrial Science and Technology (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238712-B2 | Compositions useful for the treatment of gastrointestinal disorders | GUCY1A1, TNF, GUCY1A2 | ESR1 4831/4885ESR2 4419/4885PAX8 4684/4885 |
| US-20190262420-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GUCY1A1, TNF, GUCY1A2 | ESR1 4831/4885ESR2 4419/4885PAX8 4684/4885 |
| US-20040030126-A1 | Process for synthesizing beta-lactam | COASY, QPCT, NPEPPS | ESR1 4728/4885ESR2 4759/4885PAX8 3836/4885 |
| US-20200113968-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | GUCY1A1, GUCY1A2, GUCY1B2 | ESR1 4435/4885ESR2 2942/4885PAX8 3654/4885 |
| US-20070149776-A1 | METHOD FOR PRODUCING 1,4-DIPHENYL AZETIDINONE DERIVATIVES | CYP46A1, CYP51A1, APOB | ESR1 2945/4885ESR2 1179/4885PAX8 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.